Sanofi India appoints Debajit Roy as Sales & Customer Engagement Head

Sanofi India Limited has appointed Mr. Debajit Roy as the Sales & Customer Engagement Head – Diabetes, designating him as Senior Management Personnel effective from June 8, 2026. The decision aims to strengthen the company's leadership in the Diabetes segment as it continues to drive growth across key therapy areas.

The appointment was approved by the Board of Directors via a circular resolution passed on June 3, 2026. This decision was based on the recommendation of the Nomination and Remuneration Committee, which passed its resolution by circulation on June 2, 2026. The approval from the majority of the Board was received at 11:40 a.m.

Profile of the Appointee

Mr. Roy brings over 20 years of experience driving growth, transformation, and performance across Dermatology, Specialty Care, Diabetes, and Cardiovascular therapies. Prior to this role, he served as Vice President at Gracewell Specialty and Gracemax, part of Glenmark Pharmaceuticals.

He holds an MBA in Marketing and Human Resources from the Institute of Information and Management Science in Bhubaneshwar and a Bachelor of Science from the University of Calcutta.

Appointment Details

The following table outlines the key details of the appointment:

Sr. No.	Particulars	Description
1.	Reason for change	Appointment of Mr. Debajit Roy as Sales & Customer Engagement Head – Diabetes and designated as Senior Management Personnel of the Company
2.	Date of appointment & term	Date of Appointment – With effect from June 8, 2026 Term of Appointment – Whole-time Employment
3.	Brief profile	A Business leader with over 20 years of experience driving growth, transformation, and performance across Dermatology, Specialty Care, Diabetes, and Cardiovascular therapies. In his most recent stint, he has been as Vice President -in Gracewell Specialty and Gracemax, Glenmark Pharmaceuticals. He holds degree of MBA in Marketing and Human Resources from Institute of Information and Management Science - Bhubaneshwar and Bachelor of Science from University of Calcutta.
4.	Disclosure of relationships	Not Applicable

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.22%	-1.15%	-6.28%	-27.13%	-48.45%	-58.93%

Sanofi India Limited has received an acceptance order from the Asst. State Tax Officer, Thripunithura, Kerala, dropping scrutiny proceedings initiated for the financial year 2020-21. The order, dated May 25, 2026, and received on May 26, 2026, accepts the submissions made by the company regarding alleged tax discrepancies. There is no material impact on the financial, operational, or other activities of the company as a result of this order.

The scrutiny proceedings were initiated to verify a tax amount of INR 59,77,141. The verification focused on discrepancies related to the generation of multiple e-way bills, non-generation of e-way bills, e-way bills not reported in GST returns, and excess input tax credit availed. The authority has now dropped these proceedings after accepting the company's submissions.

Details of the Order

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key details of the order are summarized below:

Authority	Asst. State Tax Officer, Thripunithura, Kerala
Nature of Action	Acceptance order issued for FY 2020-21, dropping proceedings initiated for tax verification
Date of Order	May 25, 2026
Date of Receipt	May 26, 2026
Violations Alleged	Discrepancies in e-way bills and excess input tax credit
Financial Impact	No material impact on financial, operational, or other activities

The company confirmed that the order resolves the proceedings initiated for the verification of the specified tax amount. The acceptance of the submissions by the tax authority concludes the scrutiny process for the period in question.